The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s hepatitis drugs market report forecasts the hepatitis drugs market size to grow to $23.69 Billion by 2027, with a CAGR (compound annual growth rate) of more than 5%.

Learn More On The Hepatitis Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report

Hepatitis Drugs Market Size Forecast
The global hepatitis drugs market is expected to grow from $18.63 billion in 2022 to $19.38 billion in 2023 at a compound annual growth rate (CAGR) of 4.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hepatitis drugs market size is expected to grow to $23.69 billion in 2027 at a CAGR of 5.2%.

North America held the largest hepatitis drugs market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Hepatitis Drugs Market Driver ­– Increase In Number Of Cases Of Different Types Of Hepatitis
For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1.5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

Request for A Sample Of The Global Hepatitis Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6889&type=smp

Key Hepatitis Drugs Market Trend – Launching New Product
The key players in the hepatitis drugs sector are focusing on launching new products for hepatitis treatments to strengthen their position in the market. For instance, in September 2020, MYR Pharmaceuticals, a Germany-based biotechnology company, launched HEPCLUDEX (bulevirtide) in Germany, France, and Austria for the treatment of chronic hepatitis B and D. HEPCLUDEX® is the first European drug to be approved for the treatment of chronic hepatitis D. HEPCLUDEX® inhibits the entry of HBV/HDV into hepatocytes and viral spread within the liver by blocking the NTCP receptor on the surface of hepatocytes.

Hepatitis Drugs Market Segment
1) By Drug Class: Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents
2) By Route Of Administration: Oral, Injection
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E

Hepatitis Drugs Market Major Players and Strategies
Major players in the hepatitis drugs market are Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, and Dynavax Technologies Corporation.

In March 2021, Gilead Sciences, a US-based biopharmaceutical company acquired MYR GmbH for cash consideration of $1.55 billion (€1.45 billion). As a result of the acquisition, Gilead leverages the MYR GmbH’s new drugs and expansion of the market globally in providing better treatment for hepatitis. MYR GmbH is a Germany-based company that develops inhibitors for chronic hepatitis B and D infections.

The Hepatitis Drugs Global Market Report 2023 covers regional data on hepatitis drugs market size, hepatitis drugs market trends and drivers, opportunities, strategies, and hepatitis drugs market competitor analysis. The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Hepatitis drugs refer to a medication that aggravates liver inflammation. A number of viruses (viral hepatitis), substances, medications, alcohol, certain genetic abnormalities, an overactive immune system that mistakenly assaults the liver (autoimmune hepatitis), and other factors, can result in liver inflammation.

View More Reports Related To The Hepatitis Drugs Market –
Drugs For Erectile Dysfunction Global Market Report 2023
Drugs For Benign Prostatic Hypertrophy Global Market Report 2023
Drugs For Hormonal Replacement Therapy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: